Pre-Menopause, Menopause and Beyond

Name: Pre-Menopause, Menopause and Beyond | Volume 5: Frontiers in Gynecological Endocrinology
Brand: Springer
Price: 53.49 EUR
Availability: OnlineOnly

Volume 5: Frontiers in Gynecological Endocrinology

Martin Birkhaeuser Andrea R. Genazzani(Herausgeber*in)

Springer (Verlag)

Erschienen am 30. Januar 2018

IX, 327 Seiten

E-Book

PDF mit Wasserzeichen-DRM

Systemvoraussetzungen

978-3-319-63540-8 (ISBN)

53,49 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Wasserzeichen-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Personen

Martin H. Birkhaeuser has been professor and Head of the division of Gynecological Endocrinology and Reproductive Medicine at the University of Berne from 1993 to 2008.

He is founder and first President of the Swiss "Arbeitsgemeinschaft für gynaekologische Endokrinologie und Reproduktionsmedizin" (2004-2010), and was President of the following Swiss Scientific Societies: Swiss Endocrine Society, FIVNAT-CH, Swiss Menopause Society and the Swiss Association against Osteoporosis.

Martin H. Birkhaeuser is member of the Board of the International Academy of Human Reproduction since 2012 and Treasurer of the International Society for Gynecological Endocrinology since 2014. He Honorary Founding President of the European Menopause & Andropause Society and has been Secretary General of CAMS (1998-2002) and member of the Executive Committee of the International Menopause Society (2002-2008, Treasurer 2005-2008). Martin H. Birkhaeuser is Honorary President of the Turkish Menopause Society and Honorary Member of the International Menopause Society, the Swiss Menopause Society, the Portuguese Menopause Society, the Romanian Menopause Society, the Hungarian Menopause Society and the Chilean Menopause Society.

His special interests concern menopause (bone/lipid metabolism, quality of life, impact of HRT) and the Polycystic Ovary Syndrome. In 1987 Martin H. Birkhäuser won the Schering prize for his work on Clomiphene-resistent chronic anovulation in the PCO-Syndrome.

Andrea R. Genazzani has been professor and Director of the Department of Obstetrics and Gynecology of the University of Pisa from 1994 to 2012.

He is President of the International Society of Gynecological Endocrinology (ISGE), President of the European Society of Gynecology (ESG), General Secretary of the International Academy of Human Reproduction (IAHR), Fellow ad eundem of the Royal College of Obstetricians and Gynaecologists (RCOG), Fe

llow at the American College of Obstetricians and Gynecologists (ACOG).

Andrea R. Genazzani is Editor-in-Chief of Gynecological Endocrinology since 1987. He is author of more than 828 papers in peer reviewed journals and Editor of more than 43 books.

Inhalt

Part I Menopause: symptoms and neuroendocrine impact Intracrinology made menopause possible.- From menopause to aging: endocrine and neuroendocrine biological changes.- Brain impact of sex steroids withdrawall of the menopause.- Climacteric symptoms: importance and management.- Part II Fertility 2016 IMS Recommendations on women's midlife health, "POI" and menopause hormone therapy (MHT).- Female infertility and autoimmunity.- Is IVF/ICSI/ET reasonable beyond the female age of 40 years?.- IVF: new developments in patient tailored ovarian stimulation.- Oocyte donation in peri-menopausal and menopausal women.- Part III Thyroid disorders, polycystic ovary and metabolic syndrome Thyroid disorders in climacteric women.- Thyroid function and pregnancy outcome after ART: what is the evidence?.- PCOS: implications of cardio-metabolic dysfunction.- Why Metformin is so important for prevention and treatment in climacteric women?.- Metabolic changes during menopausal trans

ition.- Weight and body composition management after menopause.- Part IV Bone and cardiovascular impact Healthy bones after menopause - what has to be done?.- The effect of menopause and HRT on coronary heart disease.- How to prevent cardiovascular disorders: influence of gonadal steroids on the heart.- Part V Benign breast diseases, BRCA mutation and breast cancer Risk reducing surgery and treatment of menopausal symptoms in BRCA mutation carriers (and other high risk women).- Benign breast disease during women's life.- Treatment of menopausal symptoms in breast cancer survivors.- Myo-inositol and Inositol Hexaphosphate (IP6) in the treatment of breast cancer.- Part VI Menopause symptoms: the therapies The true risks of hormone replacement therapy.- Menopausal hormone therapy customization.- Vulvovaginal atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM): Advances in management.- Menopause symptoms: new treatment options.- Intravaginal DHEA forthe treatment of vaginal atrophy closest to physiology.- Part VII Surgical challenges after menopause: problems and solutions Bladder dysfunction and urinary incontinence after the menopause: hormones, drugs or surgery?.- When is ovarectomy and when tubectomy indicated at necessary hysterectomies beyond the reproductive age?.- Pelvic floor reconstructive surgery in ageing women: tailoring the treatment to each woman's needs.

Systemvoraussetzungen

Als PDF speichern Als Link merken